Synopsis: **PsoBest – German Psoriasis registry on systemic antipsoriatic treatment**

Objectives: Long-term observation of systemic antipsoriatic treatment in Germany (biologics and non-biologics) with special focus on long-term effectiveness and safey in routine carse as well as on specific patient benefit.

Performance: Starting with the first application of a conventional systematic or biological agent, PsoBest documents the long-term course of patients with moderate to severe Psoriasis. Thus, patients who receive fumaric acid esters (FAE), MTX, Ciclosporin A, as well as the biologics Adalimumab, Etanercept, Infliximab, Ustekinumab and Golimumab or other systemic therapeutics can be included in PsoBest. The designated observation time per patient is ten years, disregarding the therapies being taken within this period.

Design: Multi-centre, prospective national non-interventional patient registry

Patients: Patients with plaque-type Psoriasis (Pso) or Psoriatic arthritis (PsA), age ≥18 years, being administered a specific systemic drug for the first time, written informed consent to participate, sufficient language skills (German) are included.
Patients diagnosed with pure forms of Psoriasis inversa or Psoriasis pustulosa are excluded.
Participation in clinical trials at the day of admission to the registry is not allowed, while participation in a clinical trial during the registry time is.

Visits: Visits are carried out every 3 months alternating as dermatology office visits (n= 22) and as direct mails to patients (n=19). Observation time is currently 10 years



Follow-ups with physician appointments (A) and patient contacts by mail (P)

Main criteria: clinical course (PASI), quality of life (DLQI), patient benefit (PBI), side effects.

Organisation: Begin of the registry was 01.09.2007, first patient was registered 01.12.2007. All German dermatology offices can participate and include appropriate patients in the registry. After site registration all material needed is sent, including case report forms. Forms filled out, are send to CVderm by fax or mail. New sites and patient can be registered any time.

Inclusion: For every new PsoBest patient, these steps are neccessary:

- Patient information, obtain informed consent form; have patients form filled out.
- Fill out dermatologists from and send both forms (patient and dermatologist) to CVderm.
- Fix appointment for follow-up visit.

Monitoring: The participating registry sites are visited by the CVderm at their own request and according to a fixed schedule. The objectives of the visits are to advise on the organization and implementation as well as the quality control of the documentation. The visit is reimbursed to the dermatologist at € 80.

Payment: The dermatologist will receive an expense correction of € 60 for each protocol-compliant, completed and returned visit documentation, for the inclusion visit of € 100 (since 01.07.2015).

Ethics: The positive vote of the ethics committee of the Landesärzertkammer Hamburg from 24.07.2007 is available for the psoriasis registry PsoBest. This was renewed on 07.05.2015.

Lead: The psoriasis register PsoBest is carried out by the CVderm at the University Medical Center Hamburg-Eppendorf (Head: Prof. Dr. Augustin) on behalf of the DDG and the BVDD. The project is accompanied by a scientific advisory board to which the presidents and other members of both associations belong.

Information: CVderm – German Center of Competence for Health Services Research in Dermatology
Tel. 040-7410-58109 Fax. -57227 (clinical) -44487 (person data)
Email: info@psobest.de webseite: www.psobest.de